Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial

BACKGROUND: Tisagenlecleucel yielded a high durable response rate in patients with relapsed/refractory (r/r) follicular lymphoma (FL) in the global phase 2 ELARA trial. Here, we report the efficacy, safety, and cellular kinetics of tisagenlecleucel in a subgroup of Japanese patients with r/r FL from...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuhara, Noriko, Kato, Koji, Goto, Hideki, Takeshi, Tajima, Kawaguchi, Mayu, Tokushige, Kota, Akashi, Koichi, Teshima, Takanori, Harigae, Hideo, Schuster, Stephen J., Thieblemont, Catherine, Dreyling, Martin, Fowler, Nathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889457/
https://www.ncbi.nlm.nih.gov/pubmed/36404384
http://dx.doi.org/10.1007/s12185-022-03481-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889457/
https://www.ncbi.nlm.nih.gov/pubmed/36404384
http://dx.doi.org/10.1007/s12185-022-03481-y

Ejemplares similares